253 related articles for article (PubMed ID: 2420925)
1. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.
Minor PD; John A; Ferguson M; Icenogle JP
J Gen Virol; 1986 Apr; 67 ( Pt 4)():693-706. PubMed ID: 2420925
[TBL] [Abstract][Full Text] [Related]
2. Intertypic genomic rearrangements of poliovirus strains in vaccinees.
Cammack N; Phillips A; Dunn G; Patel V; Minor PD
Virology; 1988 Dec; 167(2):507-14. PubMed ID: 2849237
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
Blomqvist S; Bruu AL; Stenvik M; Hovi T
J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
[TBL] [Abstract][Full Text] [Related]
4. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
[TBL] [Abstract][Full Text] [Related]
5. Long-term excretion of vaccine-derived poliovirus by a healthy child.
Martín J; Odoom K; Tuite G; Dunn G; Hopewell N; Cooper G; Fitzharris C; Butler K; Hall WW; Minor PD
J Virol; 2004 Dec; 78(24):13839-47. PubMed ID: 15564492
[TBL] [Abstract][Full Text] [Related]
6. Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees.
Tatem JM; Weeks-Levy C; Mento SJ; DiMichele SJ; Georgiu A; Waterfield WF; Sheip B; Costalas C; Davies T; Ritchey MB
J Med Virol; 1991 Oct; 35(2):101-9. PubMed ID: 1662701
[TBL] [Abstract][Full Text] [Related]
7. Determination of antigenic properties of vaccine derived poliovirus strains.
Pliaka V; Achilleos C; Kyriakopoulou Z; Tsakogiannis D; Ruether IG; Gartzonica C; Levidiotou-Stefanou S; Markoulatos P
Vaccine; 2010 Dec; 29(1):26-33. PubMed ID: 20974307
[TBL] [Abstract][Full Text] [Related]
8. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients.
Yoneyama T; Hagiwara A; Hara M; Shimojo H
Infect Immun; 1982 Jul; 37(1):46-53. PubMed ID: 6179881
[TBL] [Abstract][Full Text] [Related]
9. Antigenic and biochemical characterization of poliovirus type 2 isolated from two cases of paralytic disease.
Fiore L; Pierangeli A; Lombardi F; Santoro R; Crainic R; Venuti A; Perez-Bercoff R
Intervirology; 1987; 27(4):196-204. PubMed ID: 2447031
[TBL] [Abstract][Full Text] [Related]
10. [Isolation of recombinant vaccine strains of poliovirus from patients with poliomyelitis].
Kutitova OK; Lipskaia GIu; Maslova SV; Agol VI
Mol Gen Mikrobiol Virusol; 1989 Nov; (11):14-20. PubMed ID: 2560812
[TBL] [Abstract][Full Text] [Related]
11. Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping.
Minor PD; Schild GC; Ferguson M; Mackay A; Magrath DI; John A; Yates JP; Spitz M
J Gen Virol; 1982 Aug; 61 (Pt 2)():167-76. PubMed ID: 6181190
[TBL] [Abstract][Full Text] [Related]
12. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees.
Friedrich F
Acta Virol; 1996 Jun; 40(3):157-70. PubMed ID: 8891097
[TBL] [Abstract][Full Text] [Related]
13. A Sabin 2-related poliovirus recombinant contains a homologous sequence of human enterovirus species C in the viral polymerase coding region.
Zhang Y; Zhang F; Zhu S; Chen L; Yan D; Wang D; Tang R; Zhu H; Hou X; An H; Zhang H; Xu W
Arch Virol; 2010 Feb; 155(2):197-205. PubMed ID: 19946714
[TBL] [Abstract][Full Text] [Related]
14. Retrospective molecular and phenotypic analysis of poliovirus vaccine strains isolated in Greece.
Pliaka V; Filliponi ME; Kyriakopoulou Z; Ruether IG; Tsakogiannis D; Gartzonika C; Levidiotou-Stefanou S; Markoulatos P
Clin Microbiol Infect; 2011 Oct; 17(10):1554-62. PubMed ID: 21375661
[TBL] [Abstract][Full Text] [Related]
15. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
Minor PD; Schild GC; Evans D; Ferguson M; Almond J
Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
[TBL] [Abstract][Full Text] [Related]
16. Antigenic and biochemical characterization of poliovirus type 1 isolates of non-vaccine origin.
Hara M; Hagiwara A; Yoneyama T; Saito Y; Shimojo H
Microbiol Immunol; 1983; 27(12):1057-65. PubMed ID: 6328228
[TBL] [Abstract][Full Text] [Related]
17. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees.
Macadam AJ; Arnold C; Howlett J; John A; Marsden S; Taffs F; Reeve P; Hamada N; Wareham K; Almond J
Virology; 1989 Oct; 172(2):408-14. PubMed ID: 2552655
[TBL] [Abstract][Full Text] [Related]
18. Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population.
Magrath DI; Evans DM; Ferguson M; Schild GC; Minor PD; Horaud F; Crainic R; Stenvik M; Hovi T
J Gen Virol; 1986 May; 67 ( Pt 5)():899-905. PubMed ID: 3009690
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis.
Zhang Y; Wang H; Zhu S; Li Y; Song L; Liu Y; Liu G; Nishimura Y; Chen L; Yan D; Wang D; An H; Shimizu H; Xu A; Xu W
J Gen Virol; 2010 Feb; 91(Pt 2):421-9. PubMed ID: 19846676
[TBL] [Abstract][Full Text] [Related]
20. Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient.
Odoom JK; Yunus Z; Dunn G; Minor PD; Martín J
J Virol; 2008 Sep; 82(18):9179-90. PubMed ID: 18596089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
